2005.HK
2005.HK
KYG8406X1034
SSY GROUP
Loading chart...

Company Profile

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; research, development of biotechnology and related roducts; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. SSY Group Limited was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

Related stocks

0460.HK
0460.HK • Hong Kong SAR China
SIHUAN PHARM
0.74 HKD
859.65M USD 1Y -55.4%
0570.HK
0570.HK • Hong Kong SAR China
TRAD CHI MED
1.27 HKD
815M USD 1Y -47.1%
3613.HK
3613.HK • Hong Kong SAR China
TONGRENTANGCM
5.57 HKD
594.18M USD 1Y -37.8%
3933.HK
3933.HK • Hong Kong SAR China
UNITED LAB
7.52 HKD
1.89B USD 1Y -46.9%
HCM.L
HCM.L • Hong Kong SAR China
HUTCHMED (CHINA) LIMITED ORD US
203 GBp
2.33B USD 1Y -11.8%
0512.HK
0512.HK • Hong Kong SAR China
GRAND PHARMA
4.74 HKD
2.12B USD 1Y -43.5%
300267.SZ
300267.SZ • China
ER-KANG
3.36 CNY
1.04B USD 1Y -1.8%
HCM
HCM • Hong Kong SAR China
HUTCHMED (China) Limited
14.1 USD
2.45B USD 1Y -16.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.4% p.a.
Max Drawdown (5Y)
-63.6%
Sharpe Ratio (5Y)
-0.29
Beta Factor
0.48
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -78.3% in the extended horizon.
ende